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trends, investigate the coherency of reported trends, and cross-check the anticipated impact of public health interventions.
Identifying the cause(s) responsible for anomalous RTB/HIV values can reveal information crucial to the management of
public health.
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Introduction
Epidemiological monitoring presents serious challenges in both
developing and developed nations. These challenges can stem
from a lack of data, but also from a wealth of data that can be
disconnected and analyzed in non-integrative ways. Linked
epidemics can offer unique epidemiological insights when
comparing interacting disease processes [1,2], and linked analyses
can be particularly insightful if we have a solid understanding of
how the epidemics interact. Here we consider analyzing data from
closely coupled epidemics—or co-epidemics, as we will refer to
them— focusing on the use of joint indicator quantities to
integrate data based on known mechanisms of interaction.
HIV offers many dramatic examples of linked emerging and re-
emerging epidemics, because it has enhanced the ability of
numerous human and zoonotic pathogens to proliferate to
unprecedented levels [3,4]. The epidemiological patterns of
several infectious diseases are therefore tightly linked to those of
HIV: when the prevalence (total number of persons infected) of
HIV increases, so does the incidence (number of new persons with
active disease, either because of a new infection, or because an
existing infection has become activated or reactivated) and
ultimately the prevalence of associated diseases [5,6]. Tuberculosis
(TB) ranks among the most deadly and prevalent re-emerging
infections of persons living with HIV/AIDS (PLWHA). In the last
20 years the number of new TB cases has tripled in high HIV
prevalence countries, and at least 33% of the world’s 33.2 million
PLWHA are infected with Mycobacterium tuberculosis [7]. Further-
more, drug-resistant TB can be more prevalent and virulent in
PLWHA [8–10]. There is great regional variation in TB/HIV co-
dynamics: approximately 80% of persons with TB/HIV co-
infections live in sub-Saharan Africa, where TB is the leading
cause of death among PLWHA [7,11]. The TB burden is expected
to increase considerably in Eastern Europe and China, where the
HIV epidemic is still rising [12]. Fortunately, because HIV is such
a major driving force in HIV associated infections, the incidence
and prevalence of opportunistic infections have also been
documented to decrease when HIV trends decrease [13,14].
Here we focus on TB and HIV, reviewing efforts of The World
Health Organization (WHO) and collaborative agencies to track
and fight the co-epidemic. We discuss the use of mathematical
modeling to help identify appropriate disease monitoring indica-
tors, i.e. variables used to measure progress towards the goals,
objectives and targets of public health programs [15]. Indicators
specifically designed to combine information from both diseases
provide an efficient approach to integrating the available data to
obtain a more comprehensive view of the entire system, and also
facilitate spatiotemporal comparisons of disease dynamics. We
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compare the rate of change of TB incidence relative to that of HIV
prevalence, and conduct a comparative study of TB/HIV co-
dynamics across sub-Saharan Africa. We also discuss the use of
other joint indicators, and conclude by placing our suggestions
within the context of global disease monitoring.
Methods
Joint Programs for Surveillance and Control of HIV and
TB
The tightly knit co-dynamics of HIV and its opportunistic
infections have led public health officials to promote and
intensify collaborative activities among programs directed
toward HIV/AIDS care and control with those focusing on
HIV-associated diseases. WHO and collaborators have estab-
lished a Global TB/HIV Working Group, elaborating frame-
works for expanding the scope of TB and HIV programs and
their partners [15–22] with the objective of improving
diagnostic, care, and prevention services for HIV and TB
patients. The ultimate goal is to decrease the TB burden in
PLWHA and the HIV burden in TB patients [17,23,24]. In
effect, these efforts have increased the number of TB patients
worldwide who were tested for HIV and accessed HIV
prevention, treatment, and care services from 22,000 in 2002
to 700,000 in 2006. Additionally, the number of countries
implementing collaborative TB/HIV activities rose from 7 in
2003 to 112 in 2006, with Kenya, Malawi, and Rwanda
showing exceptional progress. However, much work remains.
Many HIV health care facilities are not properly equipped to
avoid TB transmission [25] and in 2006, ,1% of PLWHA
worldwide were tested for TB and only 0.08% were placed on
isoniazid preventive therapy when latently infected with TB
[26].
Monitoring and evaluation (M&E) is an essential component of
health program management [15], and involves the routine
tracking of service and program performance (monitoring)a n dt h e
episodic assessment of results of program activities (evaluation). As
resources devoted to collaborative TB/HIV activities increase, so
does the need to assess their quality, effectiveness, coverage, and
delivery beyond the tools provided by the guidelines for M&E
and lists of indicators established independently by TB and HIV/
AIDS programs [15,17,27]. For example, monitoring HIV
prevalence among TB patients is an activity linked to both
programs, and is not exclusive to either one. If neither TB nor
HIV/AIDS programs commit funds or accept responsibility for
it, key indicators may not be properly surveyed and critical
information for adequate M&E may go amiss (10). Likewise,
redundancy of research, where both programs monitor the same
indicator, should be avoided to conserve limited resources [12].
Accordingly, WHO and the TB/HIV Working Group provide
guidance for TB/HIV operational research [12], including a
framework for the collection of the most appropriate data, the
definition of a core group of indicators, and the allocation of
responsibilities specifically targeted at TB/HIV collaborative
activities [15]. Furthermore, WHO, UNAIDS and UNICEF
provide data on key performance indicators for collaborative
TB/HIV activities [11,16,28].
Joint Indicators for Linked Epidemics: The Role of
Modeling
Further efforts on behalf of WHO and collaborating agencies in
the fight against the TB/HIV co-epidemic include the establish-
ment of research priorities specifically crafted to guide policy
development (health system and policy research) and implemen-
tation of joint TB/HIV activities (operational research and
targeted evaluation) [12]. The ultimate goal of this research is to
improve preventive measures for and care of people with HIV-associated TB,
and is directed primarily toward resource-limited settings in the
context of the roll-out of antiretroviral therapy (ARVT) programs.
To this end, joint data analysis of TB and HIV co-dynamics via
mathematical, statistical, and computational approaches can yield
substantial benefits at relatively low financial cost, particularly in
the implementation of scaled up or novel public health policies
[4,14,26,29–33]. Modeling can also offer essential insight in
defining optimal indicators, which is a key step in the successful
M&E of TB/HIV collaborative activities [15], because analytical
techniques can:
N Demonstrate the purpose of measuring an indicator by exposing
how the different components of the system interact in space
and time, potentially revealing hidden inter-relationships
between different indicators. Due to the complexity of
biological systems, it may not be obvious that certain indicators
are surrogate markers for critical population-level disease
processes.
N Allow us to quantify changes in the value of key indicators in
response to disturbances to the system—such as changes in risky
behavior, treatment of infected persons, development of drug
resistance [31,32]—thereby facilitating the M&E process by
enabling us to contrast expected and reported disease trends.
N Help define the optimal methodology and periodicity for indicator
surveillance. Different surveillance schemes will generate
different data types, and modeling can show how informative
these types are in regards to particular questions (e.g. via
sensitivity analysis, see below). Modeling can also inform on
the relative importance of spatial heterogeneity in determining
indicator trends [34], allowing us to optimize the spatial scale
of data collection. Furthermore, indicators may vary in the
amount of information they can provide at different points in
time, and modeling can be used to assess the optimal timing of
epidemiological surveys.
N Inform on the strengths and limitations of different indicators by
establishing their relative importance via sensitivity and
uncertainty analyses [29,35]. Additionally, these analyses
permit us to quantify how our level of uncertainty in the
surveillance of an indicator limits our ability to infer actual
disease trends from reported trends, or to evaluate the impact
of alternative interventions.
N Provide essential insight into spatial and temporal differences
in the processes acting on the system [14]. A key attribute of an
indicator is its comparability across settings, because pandemics
such as HIV and TB have a broad geographic distribution,
and are subjected to a diverse array of conditions that can
generate regional variation in their co-dynamics.
An Indicator for TB/HIV Dynamics
We can easily quantify how each individual disease varies in
time by defining a rate of change of any given measure (i.e.
incidence, prevalence, mortality). However, in the case of closely
interacting diseases such as TB and HIV, quantifying how the two
diseases vary together may provide additional and valuable
information both for the individual monitoring of the diseases,
and for collaborative control efforts [15,16]. As such, an essential
feature of TB/HIV co-epidemiology is the fact that HIV is the
major driver of these diseases’ co-dynamics. This occurs because
HIV-infected persons are highly prone to develop active TB
Monitoring Linked Epidemics
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HIV infection [38–40]. We therefore know how HIV affects TB,
and have a general understanding of how the trends of the two
diseases are related in time [6,13,41]. Hence, a TB/HIV indicator
that can capture this causality has the potential to provide greater
dynamic insight than a static indicator that provides a one-point-
in-time measure. Ideally the dynamic indicator will compare time
trends for the two diseases that account for the time lag expected
to occur between changes in HIV numbers and changes in TB
numbers in a population. By comparing HIV trends from a time
period earlier than that considered for TB, we can incorporate this
asymmetry in the interaction between the two diseases, where HIV
drives TB and not the reverse. As a concrete example of the
application of these principles, we present and generalize a
measure that was recently applied to HIV and TB co-dynamics in
sub-Saharan Africa. This indicator, which we call RTB/HIV,
compares how fast the incidence of active TB cases (including both
smear-positive and smear-negative disease) changes in relation to
changes in the prevalence of HIV in different countries or regions.
We examine changes in TB incidence in the context of varying
HIV prevalence—rather than relative changes in the incidence of
both diseases or, alternatively, in the prevalence of both diseases—
for several reasons. On the one hand, this approach allows us to
shorten the time lag between the HIV data and the TB data used
for the indicator, because we are capturing the shortest time
interval between the measures (HIV prevalence measures people
at all stages of their HIV infection, and in principle people that
have progressed in their HIV infection will develop active TB
disease more rapidly than those only recently infected, which is
what is measured by HIV incidence). This increases the total time
period over which the indicator can be reliably calculated, because
typically we have lower quality, less reliable data the farther we go
back in time (i.e., if we compared incidence in both diseases we
would need earlier data for HIV). Additionally, HIV incidence
and TB prevalence are harder to measure, and their estimation
involves a greater number of assumptions, than their counterparts
HIV prevalence and TB incidence.
RTB/HIV is an indicator that encompasses the ratio of two
measures: RTB, which quantifies the mean change in TB incidence
(ITB) over a defined time period in the context of parameters t1, n,
and r (see below),
RTB(t1,n,r)~
ITB(t1zrzn)
ITB(t1zr)
{1
    
n,
and RHIV, which quantifies the mean change in HIV prevalence
(PHIV) over an earlier time period,
RHIV(t1,n)~
PHIV(t1zn)
PHIV(t1)
{1
    
n:
RTB/HIV is a modified ratio of these two measures,
RTB=HIV(t1,n,r)~
1zRTB(t1,n,r)
1zRHIV(t1,n)
{1: ð1Þ
Here t1=0,1,2…, is the index of time progression. The parameter n
represents the total duration of the HIV prevalence time series. We
delay the time frame of the TB data relative to that of the HIV data
by r years, to account for the average time-lag involved in individuals
developing active TB after becoming HIV infected. By doing this, we
are essentially designing an indicator measure that incorporates the
causal mechanism at play in this epidemiological interaction (see
above). To analyze any particular data set it is convenient to set t1=0
as the first year for which HIV prevalence data is available and
t1zrzn as the last year for which TB incidence data is available,
provided HIV prevalence data is available at least until t1zn (Fig. 1).
Thus, although our indicator is a single number, it evaluates changes
in TB incidence relative to HIV prevalence over a period of n years,
where n could be 1 but may be larger if data are collected on a less
than annual basis or if averaging over a longer period is desirable (or
necessary to smooth the data).
The reason for adding 1 to the rates and then subtracting 1 from
their ratio is simply to center the indicator so that it has the
intuitive properties listed in Table 1. The sign of the index tells us
which disease is increasing or decreasing relative to the other.I fT B
incidence changes at the same rate as HIV prevalence over the
period in question, then RTB=HIV(t1,n,r)~0. If TB incidence
increases relative to HIV prevalence, then RTB=HIV(t1,n,r)w0.
This result can occur either because both diseases increase and TB
does so at a faster rate, or because TB increases and HIV
decreases, or alternatively because both diseases decrease but TB
does so at a slower rate than HIV. The reverse situations will lead
to RTB=HIV(t1,n,r)v0, implying that TB incidence decreases
relative to HIV prevalence.
RTB/HIV can be used to analyze the direction of relative change
of the two diseases over time in a given geographic area (e.g. town,
district, country). However, it has added value because it is a
quantity easily comparable across different areas, such as the
Figure 1. Timeline used to generate RTB=HIV(t1,n,r) values depicted in Figure 2. The HIV time frame starts at t1=0, corresponding to 1997. In
order to track the impact of HIV on TB, we delay the TB time frame by r=3 years. Accordingly, we analyze TB data starting at t1+r=3 years, i.e. 3 years
after 1997, which corresponds to the year 2000. We have TB data until the year 2006, such that the length of our TB time frame spans 2000–2006, for
a total of n=7 years of TB data. Under our formulation this corresponds to t1+r+n=10. Because optimally we compare trends for the same number of
years for the two diseases, we also use 7 years of HIV data, t1+n=7 years, i.e. from 1997–2003. Dashed lines indicate HIV, dotted lines indicate TB.
doi:10.1371/journal.pone.0008796.g001
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Therefore one can gain insight into the epidemics’ co-dynamics
not only because of the numerical value of the measure in a given
area, but by comparing its value to neighboring areas (see below).
In any case, here we are working with an index of relative growth
rate, and consequently from a public health perspective any
imbalance generally will be more significant the higher the
absolute numbers of TB and HIV for a given region—that is, a
given difference in RTB/HIV will raise more concerns in badly-
affected areas (see below).
Results and Discussion
Case Study: TB and HIV in Sub-Saharan Africa
Recently we applied an indicator related to (1) in the course of a
study evaluating the potential impact of shortening treatment
duration for TB [14,30,33]. We focused on high HIV prevalence
areas, and used Kenya to calibrate our TB/HIV model because this
country provides a cohesive spatial monitoring unit with a sound
surveillance record for both diseases. However, our mathematical
model could not reconcile reported TB and HIV trends. In an effort
to understand TB/HIV co-dynamics in Kenya, we investigated
TB/HIV patterns in the whole of Africa by comparing the rates of
changeofTBascomparedtothoseofHIV[14].Weuseda measure
related to that shown above, with certain modifications due to data
availability. Our analysis singled out Kenya as a clear outlier
(together with two other countries), with TB/HIV co-dynamics that
were incongruous with the rest of sub-Saharan Africa because of its
notable increase in TB trends in relation to HIV trends. Possible
explanations for the mismatch included real epidemiological
differences or problems with the reported data. The latter appears
to have been the case inKenya, because followingthe completionof
our study the official trends for both diseases have been revised: TB
numbers have been revised downwards [42] and HIV numbers are
in the process of being revised upwards [43]. That is, in recent years
the decrease in HIV was overestimated in Kenya, while
improvements in the detection of TB had not been taken into
account [14,42–44]. Our joint analysis of TB/HIV data via
mathematical modeling and the RTB/HIV indicator identified the
anomalous co-dynamics rendered by paradoxical TB and HIV data
reported for Kenya in 2006 [44–47].
Here we present a re-analysis with the revised TB and HIV
numbers. We have calculated the RTB/HIV values with the
officially reported country estimates for TB incidence [42] and
HIV prevalence [43] for Africa (Figs. 1 and 2). We set r=3, i.e. we
define the optimal time lag at which to begin tracking potential
changes in TB incidence in a population as a response to changes
in HIV prevalence as 3 years [38], although r=2 or 4 would yield
rather similar results. For HIV in Kenya we are working with
preliminary ranges (the final official estimates are not yet
available), and have estimated the HIV prevalence as the mid-
point of the low and high bounds of the preliminary ranges. As
such, TB incidence in Kenya was estimated at 420 in 2000 and
384 in 2006, while the midpoint average HIV prevalence for the
same years is 10.6 and 7, respectively. The following calculations
give us Kenya’s RTB/HIV value:
RTB~
384
420
{1
    
7~{0:012
RHIV~
7
10:6
{1
    
7~{0:049
9
> > > =
> > > ;
RTB=HIV~
1z{ 0:012 ðÞ
1z{ 0:049 ðÞ
{1~0:038:
The RTB/HIV for all other countries can be calculated with the same
basic reasoning. With this re-analysis with the updated data, the
incongruency is largely resolved and Kenya’s value of RTB/HIV ranks
8
th out of 38 countries while in our earlier analysis it ranked 3
rd [14].
In any case, many sub-Saharan countries are showing a stabilization
of their TB incidence rates following a stabilization or decrease of
their HIV prevalence trends. The joint TB/HIV trends reported in
Africa therefore provide further evidence that substantial benefits
follow from decreases in HIV prevalence, in terms of concomitant
reductions in HIV-associated opportunistic infections.
Our analysis of TB/HIV co-dynamics in Africa further supports
the idea that interacting diseases can be used to monitor each
other—an innovative approach to the difficult science of disease
surveillance [14]. Analyses of this nature can be used to identify
those countries where the reported patterns of linked diseases are
incongruent. Looking beyond Kenya, our analysis reveals that TB
appears to be outpacing HIV in central Africa, particularly in
Rwanda and Burundi (RTB/HIV=0.096 in both countries), while
HIV is greatly outpacing TB in northwestern Africa, namely in
Mauritania, Senegal, and The Gambia (RTB/HIV=20.318,
20.233, and 20.085, respectively). Once we have identified the
countries with outlier co-dynamics, determining the reasons for the
imbalance should be a priority because they can reveal
information crucial to public health. These reasons may relate to
epidemiological mechanisms or surveillance issues or both. For
example, if TB is growing disproportionately compared to HIV
(indicated by a high value of RTB/HIV), possible causes could
include social conditions linked to poverty, malnutrition and high
population density, which can boost TB transmission, or else the
spread of more transmissible and virulent TB strains. However,
changes in surveillance practices could also contribute or explain
the mismatch. Conversely, a disproportionate relative increase in
HIV (indicated by low RTB/HIV values) may indicate that HIV
prevention programs are not effective, and that we can expect to
Table 1. Value of RTB/HIV (R in the table) as determined by the relative rates of the TB and HIV epidemics.
HIV increases HIV constant HIV decreases
TB increases R.0 if: TB increase . HIV increase
R=0if: TB increase = HIV increase R.0 R.0
R,0 if: TB increase , HIV increase
TB constant R,0 R=0 R.0
TB decreases R.0 if: TB decrease , HIV decrease
R,0 R,0 R=0if: TB decrease = HIV decrease
R,0 if: TB decrease . HIV decrease
doi:10.1371/journal.pone.0008796.t001
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help us predict possible disease trends in the near future.
Joint Epidemiological Indicators: An Open Field
Studying epidemiological trends of linked infections yields spatial
information to include in epidemiological assessments at both small
and large spatial scales, spanning regional, country, and district
levels. For example, a finer-grained analysis of Kenyan data shows
that TB growth in relation to HIV trends is proportionally much
higher in the Nairobi district than in the Kisumu district, which
could reflect environmental factors favoring TB spread in the high-
density settlements around Nairobi [14].
Joint indicators can also be used to investigate the temporal
coherency of epidemiological trends from the same area by
comparing changes in different time frames from the same
localities. We expect the RTB/HIV of a specific area or country to
vary within certain limits over time; accordingly, this indicator can
reveal unexpected co-dynamics with data collected independently
by TB and HIV control programs for other purposes. Unexpected
RTB/HIV values can result, for example, from TB and HIV
programs placing greater resources in monitoring their corre-
sponding diseases in different areas at different times, which can
yield distorted district and aggregated country estimates. Unequal
distribution of public health resources, such as skewed drug
delivery programs or imbalanced geographic placement of TB and
HIV clinics [34] can also result in differential TB/HIV patterns
that can be captured by measures such as RTB/HIV.
Another important aspect of the analysis of joint epidemiolog-
ical indicators is that we can interpret changes to their values in
the context of changing control programs for one or both diseases.
As an example (Fig. 3), we anticipate that if antiretrovirals are
newly introduced into a population, HIV numbers will decrease
and in consequence, with a certain time lag, TB numbers will also
decrease. Within this predictive scenario, we can compare
expected trends with observed trends in order to see if TB control
is reaping the benefits expected from the progressive reduction in
HIV numbers, and if so by what magnitude, quantified in terms of
a joint indicator. By quantifying with a common measure the
relative decrease of TB (or any other opportunistic infection) in
relation to HIV, we will facilitate comparing the benefits obtained
across populations. Comparing data across populations is an
excellent research tool that substitutes for ethically unacceptable
experimental approaches. As such, anomalous or outlier trends
will indicate those localities where benefits are either lower or
higher than expected or commonly reported. By identifying these
localities we can better investigate which pre-existing conditions,
drug delivery systems, ecological settings, or any other relevant
factors may maximize TB control benefits in the presence of
HIV antiretroviral programs. On the other hand, a reduction in
RTB/HIV is expected if a scale-up in TB control programs is
implemented while HIV programs remained at comparable
implementation levels.
Different questions will benefit from defining and using different
joint disease indicators. Naturally, we expect there to be a trade off
between the complexity of calculating an indicator, the data it
requires, the information it provides, and the ease with which it
can be adopted by researchers and monitoring agencies. In
conjunction, these factors will ultimately determine its usefulness in
Figure 2. RTB=HIV(t1,n,r) for Africa for the time point t1 corresponding to the year 1997. Here n=7 and r=3. This index quantifies the
change in TB incidence per 100,000 over the period 2000–2006 relative to the change in percent HIV prevalence over the period 1997–2003.
doi:10.1371/journal.pone.0008796.g002
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are very appealing. However, complex indicators may provide
more insight and there use may be warranted in finer analyses—
particularly when oddities surface that need to be investigated
further. Above we present a relatively simple joint indicator, RTB/
HIV (1), which is not difficult to compute and is easily understood.
However, its comparability across datasets is limited because it is not
standardized. We can modify RTB/HIV by normalizing, thus
transforming the measure for each individual country into a
dimensionless z-score joint indicator, ZTB/HIV:
ZTB=HIV(t1,n,r)~
RTB=HIV(t1,n,r){ R RTB=HIV(t1,n,r)
sTB=HIV(t1,n,r)
:
Here RTB/HIV corresponds to the measure (1) for a given country,
 R RTB=HIV is the mean of all of the individual country RTB/HIV for a
given dataset, and sTB=HIV is the standard deviation of RTB/HIV
for this particular dataset. In the case of the two datasets discussed
here—the TB and HIV data for Africa available in [14] and the
one available at present, see above—the mean of the first dataset is
0.067 and of the second is 20.015, while the corresponding
sTB=HIV are 0.085 and 0.070. Thus, the ZTB/HIV for Kenya is
1.508 in the first dataset and 0.752 in the second (their RTB/HIV
were 0.195 and 0.038, respectively). Therefore, the updated
Kenyan TB and HIV estimates indicate that the relative growth of
new TB cases in regards to HIV prevalence is actually
approximately half of what was reported in 2006, which reduces
the fear that some anomalous conditions are promoting an
uncontrollable TB surge in Kenya.
With this example we can see how although ZTB/HIV requires
us to do further calculations beyond computing all the RTB/HIV
values for the data of interest, it provides additional insights over
these RTB/HIV values because it allows us to account for different
Figure 3. Schematic illustrating the population-level response of the HIV and TB epidemics to a novel HIV control measure. The
relative growth rates of percent HIV prevalence (solid line) and TB incidence (dashed line) epidemics before and after the novel intervention (which
for example could be the delivery of a new antiretroviral) are captured by RTB=HIV(ti,n,r) in three different time intervals i=1, 2 and 3. These intervals
start before the novel intervention (with t1 representing the first year for which we have data), when the novel intervention is first implemented (at
year t2), and for the period starting at the point when TB incidence first decreases in scenario A (at year t3). Years t2 and t3 are represented by vertical
lines. Because this diagram is a simple schematic we will not define exact values for the parameters ti, n and r. While in both scenarios HIV prevalence
decreases, in (A) TB incidence decreases after a certain time lag such that (omitting subscripts and common argument values)
R(t1A)~R(t3A)~0vR(t2A), while in (B) TB incidence continues to increase and R(t1B)vR(t2B)vR(t3B), indicating that TB control is not reaping
the benefits anticipated from the new HIV control measure.
doi:10.1371/journal.pone.0008796.g003
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RTB/HIV ad i r e c tc o m p a r i s o nb e t w e e nt h et w oa n a l y s e si s
complicated by the fact that in [14] we used TB case
notifications because of concerns with the reliability of the data,
w h i l eh e r ew ea r eu s i n gt h em o r ed e s i r a b l em e a s u r eo fT B
incidence. The values of these two indicators can vary
substantially, and in consequence the RTB/HIV values also are
very different between the two datasets. However, when
standardizing with ZTB/HIV we facilitate comparing datasets
representing different indicators characterized by different units
of measurement.
If we needed to investigate questions such as causes of mortality
or biases in death reporting systems, we could define indicators
that for example compare mortality trends in the interacting
diseases, or incidence and mortality trends. Additionally, with the
joint indicators RTB/HIV and ZTB/HIV defined here we are
averaging over the time period of choice, and thus will miss any
irregularities that occur within the time period. If there are
important non-monotonicities in the data such as peaks or troughs,
we may benefit from quantifying trend differences not just at the
beginning and end of a lengthy time interval, but on a year-to-year
(or month-to-month, etc.) comparison. In this case we could
average the, for example, year-to-year changes in the trends of
both diseases over a certain time period, and then compare the
changes in these yearly rates.
As with any other epidemiological measure, the reliability of a
joint indicator will be determined by the quality of the
surveillance system. We can calcu l a t ec o n f i d e n c ei n t e r v a l sf o r
our joint indicators that will give an indication of the likely range
in which the value of the indicator will fall. Again, however, the
reliability of these intervals will be determined by the reliability of
the data. In any case, regardless of the statistical complexities we
add to our analyses, the main value of using joint indicators for
epidemiological monitoring lies in the fact that when contrasting
patterns of closely interacting diseases these indices will provide
insights into how the diseases are changing with respect to one
another over time, in addition to the purely temporal trend
information we have of each disease on its own. If the monitoring
of one or both diseases is systematically flawed, then anomalous
values of the joint indicator will highlight the need for closer
scrutiny.
Looking Forward: The Broader Context
The methodical integration and analysis of epidemiological
data for interacting epidemics, both individually and jointly,
provides information critical to the design of effective public
health measures. The ultimate value of epidemiological indica-
tors, whether for single or linked epidemics, lies in their
continued usage over a large proportion of the area covered by
an epidemic. The more analyses that are conducted and that can
be compared, the more useful an indicator will be. Here we
outline key steps in the process of disease monitoring and
evaluation, highlighting the use of indicators and analytical
techniques relevant to the study of closely linked epidemics. Most
of these steps are already being implemented by the correspond-
ing monitoring agencies in many countries and by supra-national
agencies.
1. Individual and joint population-level disease indicators must be
monitored [15,16,48]. It would be valuable to extend this
practice to evaluate the co-dynamics of different strains of the
linked diseases, particularly regarding drug-resistant strains
[4,31,32]. Data should be ‘‘broken down and reported by the
smallest administrative unit possible’’ [15].
2. Consistent statistical guidelines need to be established for
calculating uncertainty ranges for individual and joint measures
comparable across all spatial scales.
3. Analyses of long-term temporal trends of key indicators [17] at
multiple spatial scales should be conducted using standardized
methods in order to ensure the clear communication of
analyses and results among monitoring agencies, research
groups, and public health personnel. Ideally these analyses
should include composite temporal measures as discussed
above [14], and graphical and geographic information systems
(GIS) analyses whenever applicable.
4. Protocols for acceptable mathematical models need to be
developed [49] to analyze past and present trends, and predict
future trends. Close collaboration between monitoring agencies
and mathematically specialized personnel with training in the
dynamics of infectious diseases is strongly recommended.
5. Guidelines should be established for appropriate response to
unanticipated epidemiological patterns. These guidelines
should identify the personnel of local, national, and supra-
national agencies to whom anomalies can be reported, so that
further evaluation can take place to identify the underlying
cause(s) and prepare suitable response measures.
6. To maximize the utility of data, methods, analyses, and results,
information should be disseminated publicly in formats
understandable by personnel of different backgrounds
[12,15,16,50].
Conclusions
Advocating, designing, planning and evaluating public health
actions rely on sound data analyses [16,51]. Integrating informa-
tion from diverse sources can maximize both our understanding of
co-infection epidemiology, and our ability to predict accurately the
effectiveness of different public health interventions [1]. Accord-
ingly, comprehensive analyses are indispensable for achieving
proper integration of TB/HIV collaborative activities, and are
critically needed with the on-going scale-up of ARVT programs
[12]. Furthermore, M&E of collaborative TB/HIV activities
promote a ‘‘learning culture’’ within the programs that guarantees
continuous improvement [17]. In our experience, integrating TB
and HIV clinical and epidemiological data via a mathematical
model, and comparing TB/HIV national trends across Africa via
a simple composite measure, permitted us to infer the incon-
gruency of Kenyan TB and HIV estimates. The effort invested in
the mathematical model and in the pan-African analysis with the
joint co-epidemic indicator, although substantial, was much less
than the effort of conducting and evaluating additional surveys.
However, the insights provided by our analyses are valuable within
the context of TB/HIV global monitoring. Although HIV
prevalence among TB patients is probably the most sensitive
and reliable indicator for the TB/HIV co-epidemic [17], in our
study the relative growth rate of the two diseases, characterized by
RTB/HIV, was even more informative for evaluating Kenyan TB/
HIV trends [14]. Importantly for their broad applicability, indices
such as RTB/HIV can be calculated with the joint analysis of data
that are gathered regularly and independently by monitoring
agencies. We therefore argue that simple indicators specifically
designed to integrate information from closely linked diseases can
allow us to gauge how the co-dynamics of epidemics are changing
in time, and are powerful tools for spatial comparisons. If used as a
routine monitoring tool, these joint indicators could allow public
health officials to maximize the use of existing data by evaluating a
single number.
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